List of Bijuva drug patents

Bijuva is owned by Therapeuticsmd Inc.

Bijuva contains Estradiol; Progesterone.

Bijuva has a total of 21 drug patents out of which 0 drug patents have expired.

Bijuva was authorised for market use on 28 October, 2018.

Bijuva is available in capsule;oral dosage forms.

Bijuva can be used as treatment of menopause symptoms, including vasomotor symptoms.

The generics of Bijuva are possible to be released after 21 November, 2032.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US8987237 THERAPEUTICSMD INC Natural combination hormone replacement formulations and therapies
Nov, 2032

(9 years from now)

US10639375 THERAPEUTICSMD INC Progesterone formulations
Nov, 2032

(9 years from now)

US11110099 THERAPEUTICSMD INC Natural combination hormone replacement formulations and therapies
Nov, 2032

(9 years from now)

US8993548 THERAPEUTICSMD INC Natural combination hormone replacement formulations and therapies
Nov, 2032

(9 years from now)

US11103516 THERAPEUTICSMD INC Natural combination hormone replacement formulations and therapies
Nov, 2032

(9 years from now)

US10206932 THERAPEUTICSMD INC Natural combination hormone replacement formulations and therapies
Nov, 2032

(9 years from now)

US8846649 THERAPEUTICSMD INC Natural combination hormone replacement formulations and therapies
Nov, 2032

(9 years from now)

US8846648 THERAPEUTICSMD INC Natural combination hormone replacement formulations and therapies
Nov, 2032

(9 years from now)

US9114146 THERAPEUTICSMD INC Natural combination hormone replacement formulations and therapies
Nov, 2032

(9 years from now)

US9114145 THERAPEUTICSMD INC Natural combination hormone replacement formulations and therapies
Nov, 2032

(9 years from now)

US10675288 THERAPEUTICSMD INC Natural combination hormone replacement formulations and therapies
Nov, 2032

(9 years from now)

US9301920 THERAPEUTICSMD INC Natural combination hormone replacement formulations and therapies
Nov, 2032

(9 years from now)

US11033626 THERAPEUTICSMD INC Progesterone formulations having a desirable pk profile
Nov, 2032

(9 years from now)

US9006222 THERAPEUTICSMD INC Natural combination hormone replacement formulations and therapies
Nov, 2032

(9 years from now)

US10806740 THERAPEUTICSMD INC Natural combination hormone replacement formulations and therapies
Nov, 2032

(9 years from now)

US11103513 THERAPEUTICSMD INC Natural combination hormone replacement formulations and therapies
Nov, 2032

(9 years from now)

US8933059 THERAPEUTICSMD INC Natural combination hormone replacement formulations and therapies
Nov, 2032

(9 years from now)

US11166963 THERAPEUTICSMD INC Natural combination hormone replacement formulations and therapies
Nov, 2032

(9 years from now)

US8633178 THERAPEUTICSMD INC Natural combination hormone replacement formulations and therapies
Nov, 2032

(9 years from now)

US10052386 THERAPEUTICSMD INC Progesterone formulations
Nov, 2032

(9 years from now)

US8993549 THERAPEUTICSMD INC Natural combination hormone replacement formulations and therapies
Nov, 2032

(9 years from now)

Drugs and Companies using ESTRADIOL; PROGESTERONE ingredient

Market Authorisation Date: 28 October, 2018

Treatment: Treatment of menopause symptoms, including vasomotor symptoms

Dosage: CAPSULE;ORAL

How can I launch a generic of BIJUVA before it's patent expiration?
More Information on Dosage

Bijuva is owned by Mayne Pharma.

Bijuva contains Estradiol; Progesterone.

Bijuva has a total of 1 drug patent out of which 0 drug patents have expired.

Bijuva was authorised for market use on 28 October, 2018.

Bijuva is available in capsule;oral dosage forms.

The generics of Bijuva are possible to be released after 21 November, 2032.

Patent Number Company Patent Title Patent Expiry Activity Alert
These patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc).
US11529360 MAYNE PHARMA Natural combination hormone replacement formulations and therapies
Nov, 2032

(9 years from now)

Drugs and Companies using ESTRADIOL; PROGESTERONE ingredient

Market Authorisation Date: 28 October, 2018

Treatment: NA

Dosage: CAPSULE;ORAL

How can I launch a generic of BIJUVA before it's patent expiration?
More Information on Dosage

availability in other generic markets.

Click on the highlighted region to filter.

900+ leading pharmaceutical companies are staying up-to-date with drug patents through Pharsight

Join them to stay ahead in capturing the next drug going generic